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Abstract 
 
The tumor-homing pentapeptide CREKA specifically homes to tumors by binding to fibrin and 
fibrin-associated clotted plasma proteins in tumor vessels. Previous results show that CREKA-
coated superparamagnetic iron oxide particles can cause additional clotting in tumor vessels, 
which creates more binding sites for the peptide. We have used this self-amplifying homing 
system to develop theranostic nanoparticles that simultaneously serve as an imaging agent and 
inhibit tumor growth by obstructing tumor circulation through blood clotting. The CREKA 
nanoparticles were combined with nanoparticles coated with another tumor-homing peptide, 
CRKDKC, and nanoparticles with an elongated shape (nanoworms) were employed for 
improved binding efficacy. The efficacy of the CREKA peptide was then increased by replacing 
some residues with non-proteinogenic counterparts, which increased the stability of the peptide 
in the circulation. Treatment of mice bearing orthotopic human prostate cancer tumors with the 
targeted nanoworms caused extensive clotting in tumor vessels, whereas no clotting was 
observed in the vessels of normal tissues. Optical and magnetic resonance imaging confirmed 
tumor-specific targeting of the nanoworms, and ultrasound imaging showed reduced blood flow 
in tumor vessels. Treatment of prostate cancer mice with multiple doses of the nanoworms 
induced tumor necrosis and highly significant reduction in tumor growth.  
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Introduction 
 
The prevalence of prostate cancer and the large number of deaths from this disease underscore 
the need for a paradigm shift in the strategies to better treat this cancer 1. Since the 1970’s, 
progress in fundamental cancer biology has led to enormous advances in our understanding of 
the processes that underlie malignant transformation and metastatic dissemination. 
Nonetheless, eradication of cancer remains an elusive clinical goal, largely due to the 
heterogeneous nature of individual cancers and our inability to target therapies to neoplastic 
cells without damaging normal tissues. Prostate tumors are anatomically, histologically and 
genetically heterogeneous 2-4, causing variable responses to various therapies. These obstacles 
are further magnified by our limited ability to image cancerous regions and track the progression 
of treatments 5-6. 
 
One approach to overcome the heterogeneity of tumors is to focus on tumor vasculature. Tumor 
vasculature has proven to be particularly well suited as a site for homing-based (synaphic) 
targeting. It expresses a multitude of molecules that are not expressed in the vessels of normal 
tissues, and the vascular wall is readily accessible for blood-borne substances 7. Most vascular 
strategies use anti-angiogeneic therapy to prevent formation of new blood vessels in a growing 
solid tumor; these approaches have been found to be useful, particularly in treating advanced-
stage cancers 8-12. An alternative strategy is based on occluding the vasculature of a tumor and 
thereby inducing tumor necrosis. Targeting of truncated tissue factor to tumors has been used 
for this purpose with some success 13-17. Nanomedicine is an emerging field that uses 
nanoparticles to facilitate the diagnosis and treatment of diseases. Nanoparticles can be 
engineered to perform multiple functions, which provide a potential advantage over simple 
drugs. In this study we designed nanomedicine-based approaches to more effectively and 
safely block the tumor circulation. 
 
Our laboratory screens phage-displayed peptide libraries in vivo and ex vivo to discover specific 
targets in tumor vessels 18. Some of the tumor-homing peptides we have identified in this 
manner recognize products of blood clotting on the walls of tumor vessels and in tumor stroma 
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that are not present in normal vessels and tissues. The reasons for this difference are thought to 
be a pro-coagulant tumor environment and seepage of plasma proteins including fibrinogen, 
from the leaky tumor vessels into the tissue 19-20. We have identified three tumor-homing 
peptides that recognize these clotting products in the vessels of a variety of tumor types, 
including human cancers 21-22. Tumors grown in mutant mice null for fibrinogen, or mice lacking 
plasma fibronectin, which becomes covalently bound to fibrin during blood clotting, are not 
recognized by these peptides, indicating that the peptides target fibrin-fibronectin complexes.  
 
We have recently used one of the peptides that recognize fibrin-fibronectin complexes, a 
pentapeptide with the sequence CREKA, to design a self-amplifying nanoparticle delivery 
system 22. Iron oxide nanoparticles coated with this peptide accumulate in tumor vessels, where 
they induce additional local clotting, and thereby produce new binding sites for more particles. 
This amplification system enhanced homing of the nanoparticles in a mouse tumor model 
without causing clotting or other obvious side effects elsewhere in the body. The self-amplified 
tumor accumulation produced enhancement of tumor imaging, but significant inhibition of tumor 
growth was not obtained. We set out to develop an effective theranostic system based on the 
earlier findings using prostate cancer as the target tumor.  
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Methods 
 
Cell lines and tumors. The 22Rv1 prostate cancer cell line was obtained from American Type 
Culture Collection (Manassas, VA). The cells were grown in RPMI 1640 media supplemented 
with 2 mM glutamine, 1% penicillin-streptomycin, and 10% FCS at 37oC and 5% CO2. 
Xenografts were created by injecting BALB/c nude mice with 2 X 106 cells in PBS, orthotopically 
into the prostate gland. The LAPC9 human prostate adenocarcinoma xenograft was from Dr. 
Lily Wu (University of California, Los Angeles) and used to produce tumors as described 23. 
Animal experimentation was performed according to procedures approved by the Animal 
Research Committee at the University of California, Santa Barbara, and the Sanford-Burnham 
Medical Research Institute, San Diego. 
 
Peptide synthesis. Peptides were synthesized with an automatic microwave assisted peptide 
synthesizer (Liberty; CEM, Matthews, NC) using standard solid-phase Fmoc/t-Bu chemistry with 
2-(1H-7-Azabenzotriazol-1-yl)-1,1,3,3-tetramethyl uronium hexafluorophosphate 
Methanaminium (Anaspec, Inc., San Jose, California, USA) as the coupling reagent. During 
synthesis, the peptides were labeled with 5(6)-carboxyfluorescein (FAM) (Sigma-Aldrich, St. 
Louis, MO USA) with a 6-aminohexanoic acid spacer separating the dye from the sequence. 
The peptides were cleaved from the resin using 95% Trifluoroacetic acid (Sigma-Aldrich, St. 
Louis, MO, USA) with 2.5 % water and triisiopropylsilane (Sigma-Aldrich, St. Louis, MO USA). 
Subsequent purification by High Performance Liquid Chromatography (Gilson Inc., Middleton, 
Wisconsin, USA) gave peptides with > 90% purity. The preparation of the non-proteinogenic 
amino acids used for the synthesis of the N/Cα-methylated CREKA analogs will be reported 
elsewhere. The synthesis of CRKDKC with an extra N-terminal cysteine used for the 
chemoselective ligation used in this work will be described elsewhere.  
 
Computer modeling. The conformational profiles of the CREKA analogs, which were 
constructed by replacing each residue (one-by-one) by its N-methyl or Cα-methyl counterpart, 
were characterized by Molecular Dynamics simulations. Methodology and clustering analyses 
were as described in 24.  
 
Preparation of NW and Ni-liposomes. NW 25, NW coated with peptides and Ni-liposomes were 
prepared as described 22. The aminated nanoworms were pegylated with maleimide-5KPEG-
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NHS (JenkemTechniology, China). In the experiments where the Ni-liposomes were used, the 
nanoworms were functionalized for subsequent peptide coupling with (N-[α-
maleimidoacetoxy]succinimide ester (AMAS), (Pierce, Rockford, IL). Peptides were conjugated 
to the nanoparticles using Michael addition reaction between the thiol from a cysteine in the 
peptide sequence and the maleimide on the functionalized particles.  
 
In vivo peptide homing. Orthotopic prostate cancers were used when they reached 0.5-1 cm in 
size. Synthetic peptides labeled with FAM (approximately 200 μg) were intravenously injected 
into tumor-bearing mice and allowed to circulate for 15 minutes to 3 hours. The mice were 
perfused with PBS through the heart under anesthesia, and tissues were collected and 
observed under UV light (Illumatool Bright Light System LT-9900, Lightools Research, 
Encinitas, CA), and then processed for immunofluorescence or immunohistochemistry.  
 
In vivo NW injections. To analyze NW biodistribution, mice bearing orthotopic 22Rv1 tumors 
were injected into the tail vein (5 mg of iron per kg body weight). In homing experiments, the 
mice were euthanized 5-6 hours after the injection by cardiac perfusion with PBS under 
anesthesia, and organs were dissected and analyzed for particle homing. In tumor treatment 
experiments, nude mice bearing 2 week-old 22Rv-1 or LAPC9 orthotopic xenografts (typically 
about 200-250 mm3 in tumor volume) were intravenously injected with NW in 150 μl PBS or 
PBS as a control. The NW were injected every other day for 14 days. The total cumulative dose 
was 35 mg iron/kg. At the end of the treatment, the mice were perfused with PBS under 
anesthesia and the tumors were harvested. Tumor volume was calculated using the following 
formula: volume = (d2 × D)/2, where d is the smallest and D are the largest tumor diameters 26. 
Peptide stability. The peptides were conjugated with a linker that bridges the NW and a cysteine 
residue on the peptide, forming a disulfide by reacting with the (ortho-pyridyl)disulfide group. 
The peptide-coated NW were injected into animals, and blood was collected 15 minutes and 3 
hours after the injection. The plasma was separated and NW were collected by 
ultracentrifugation (100,000 × g for 10 minutes at 4˚C). Proteins bound to the NW were removed 
by incubation with glycine-HCl, pH 2.8 on a magnetic LS columns (MACS separation columns, 
Miltenyi Biotec, Bergisch Gladbach, Germany). The peptides were cleaved from the NW by 
incubating with 10mM dithiothreitol for 30 minutes at room temperature. The iron oxide was 
separated from the peptide by ultracentrifugation (100,000 × g for 10 minutes at 4˚C) and the 
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supernatant fractions containing the peptide were analyzed by matrix-assisted laser desorption 
ionization-time of flight (MALDI-TOF) mass spectrometry. 
 
Immunofluorescence and Immunohistochemistry. Tissues from mice injected with nanoparticles 
were fixed in 4% paraformaldehyde overnight at 4°C, cryo-protected in 30% sucrose overnight 
and frozen in OCT embedding medium. For histological analysis, 7-μm sections were cut and 
sections were H&E stained. 
 
For immunostaining, tissue sections were first incubated for 1 hour at room temperature with 
10% serum from the species in which the secondary antibody was generated, followed by 
incubation with the primary antibody overnight at 4°C. The following antibodies were used: rat 
monoclonal anti-mouse CD31 (10 μg/mL; BD Pharmingen, San Jose, CA), mouse fibrin(ogen) 
antiserum (1:100; Nordic, Tilburg, Netherlands). The primary antibodies were detected with 
Alexa 647 goat anti-rat, and 647 donkey anti-goat secondary antibodies (1:1000; Molecular 
Probes, Eugene, OR). Each staining experiment included sections stained with secondary 
antibodies only as negative controls. Nuclei were counterstained with DAPI (5 μg/mL; Molecular 
Probes). The sections were mounted in gel/mount mounting medium (Biomeda, Foster City, CA) 
and viewed under a Fluoview 500 confocal microscope (Olympus America, Center Valley, PA). 
 
For immunohistochemical staining of frozen tissue sections, endogenous peroxidases were 
quenched with 3% H2O2 (DAKO-Cytomation). Sections were blocked for 1 hour in 5% Donkey 
serum in Dako cytomation Ab dilution solution. Sections were treated with DAKO Biotin/Avidin 
Blocking system; incubated overnight at 4°C with mouse fibrin(ogen) antiserum. The primary 
antibody was detected with biotinylated anti-mouse IgG and Vectastain ABC kit (Vector 
Laboratories, Burlingame, CA). Nuclei were counterstained with hematoxylin (Vector 
Laboratories Burlingame, CA). To quantify the homing area of fibrin(ogen) within tumors the 
stained section were scanned with the Scanscope CM-1 scanner and analyzed with the 
ImageScope software41 (Aperio Technologies, Vista, CA). 
 
Apoptosis was determined using the terminal deoxynucleotidyl transferase–mediated 
deoxyuridine triphosphate nick end labeling (TUNEL) assay for the identification of double-
stranded DNA breaks using the In situ Cell Death Detection Kit (Roche Applied Science, 
Indianapolis, IN), according to the manufacturer's instructions. 
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Magnetic resonance imaging. Nude mice bearing 22Rv-1 orthotopic human prostate cancer 
xenografts were intravenously injected with superparamagnetic iron oxide NW coated with 
peptides, or left not coated at a dose of 5 mg of iron per kg body weight. Each animal received 
Ni-liposomes (0.2 mmol of Ni) intravenously 1 hour prior to the NW to increase the blood half-life 
of the NW. Approximately 7-8 hours after the NW injection, the mice were anesthetized with 
isoflurane and subjected to T2-weighted MRI scans with a 3-Tesla MR imager (GE Healthcare 
Technologies, Milwaukee, WI). After imaging, tissues of interest were harvested and processed 
for immunofluorecence.  
 
Contrast-enhanced ultrasound (CEUS). Definity® contrast agent (Lantheus Medical Imaging; 5 
µl in 45 µl of saline) were injected into the tail vein of mice using a 28 gauge insulin syringe. 
Philips iU22 with a L12-5 transducer was used for imaging with a low mechanical index (MI), 
contrast specific imaging mode (power modulation mode). The imaging parameters were set as 
follows and kept identical throughout the study: depth 2 cm, focus zone 2 cm, MI 0.06, 5 frames 
per second. Two-minute cine loop was saved for time intensity curve analysis using Philips 
QLab. CEUS was performed prior to, 1, 3, and 6 hours after injection of mice with CREKA-NW 
alone or in combination with CRKDKC-NW. The tumor rim, center, and the surrounding tissue 
were separately examined to quantify the efficiency of tumor circulation. CEUS analysis of 
tumors treated for 2 weeks with the NW was carried out using Photoshop with a threshold 
method, in which the pixels with enhancement and those without were counted (the threshold 
was set arbitrarily, as there was no fixed number). The percent area with enhancement = the 
pixel number of the enhanced area/the pixel number of the entire tumor x 100.  
 
Statistical analysis. Data were analyzed by two-tailed Student's unpaired t-test or one-way 
analysis of variance (ANOVA) followed by suitable post-hoc test. P values of less than 0.05 
were considered statistically significant. 
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Results 
 
Nanoworm combinations for enhancing the activity of CREKA nanoparticles  
 
We used elongated iron oxide nanoparticles, “nanoworms" (NW), which are more effective in 
peptide-mediated cell binding than spherical particles 25. Nanoworms (NW) coated with the 
CREKA peptide accumulated in the vessels of orthotopic 22Rv1 human prostate cancer 
xenograft tumors and caused clotting in them, as evidenced by the presence of fibrin(ogen)-
containing deposits in the vessel lumens (Figure 1a). In tumors of untreated mice (not shown) or 
mice treated with nanoparticles coated with peptides other than CREKA, mainly the blood 
vessel walls were positive for fibrin(ogen) (Figure 1b). Most of the increased fibrin(ogen) 
staining in the CREKA-NW-treated 22Rv1 tumors was in the tumor periphery, whereas little NW 
accumulation or clotting was seen in the center of the tumors. 
 
We hypothesized that it might be possible to improve the tumor delivery of NW by combining 
CREKA with a tumor-homing peptide that recognizes a different target molecule other than 
CREKA, and therefore potentially binds to different vessels in the tumor. We tested two tumor-
homing peptides for their ability to increase CREKA-NW homing: CRKDKC, which was originally 
identified as a wound-homing peptide 27, and CGKRK 28. Both peptides bind to the blood 
vessels in various kinds of tumors 27-28. Both CRKDKC-NW and CGKRK-NW accumulated in 
more than 70% of the 22Rv1 tumor vessels as evidenced by colocalization with CD31 staining 
(Figure 1b, Supplementary Figure 1).  
 
We next tested NW double-coated with CREKA and one of the other peptides. However, the 
double-coated NW showed only minimal tumor homing (Supplementary Figure 2). It may be that 
coating the nanoparticles with two different peptides on the same nanoparticle reduces the 
surface density of each peptide to an extent that adversely affects the homing. Surprisingly, we 
found that mixtures of CREKA-NW with CRKDKC-NW or CGKRK-NW, which were used as 
controls, were quite effective in delivering CREKA-NW to vessels in the tumor interior and 
causing clotting in them. The mixed single-peptide particles may aggregate in tumor vessels, 
making it possible for each peptide to carry both types of particles to the target. Among the 
particle mixtures, the CREKA-CRKDKC mixture was particularly effective in homing to the entire 
tumor (Figure 1c), and we subsequently focused on this combination. Quantification of 
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fibrin(ogen) accumulation showed that combining CREKA-NW with CRKDKC-NW enhanced 
clotting by 4-5 fold compared to CREKA-NW alone (Figure 1d). Contrast-Enhanced Ultrasound 
(CEUS) Imaging showed a 90% reduction in blood flow at 6 hours after the injection of the NW 
mixture (Figure 2).  
 
Enhancing the activity of CREKA by incorporation of non-coded amino acids  
 
We hypothesized that protecting CREKA against proteolytic degradation may further increase 
the efficacy of the tumor homing. Proteolysis protection can be achieved through the 
incorporation of non-proteinogenic amino acids, provided that the bioactive conformation of the 
peptide is retained 24,29. Based on molecular modeling studies 24, several N- and Cα-methylated 
amino acids were selected to replace the key residues in CREKA. This chemical modification 
can be viewed as the methylation in certain positions of the peptide backbone (at either N or 
Cα). These studies indicated that the N-methylation and Cα-methylation of the Arg, Glu and Lys 
residues does not affect the conformational profile of the peptide (Supplementary Figure 3). The 
CREKA analogs incorporating the N/Cα-methylated amino acids were synthesized as 
fluorescein (FAM)-labeled peptides. Several of the CREKA analogs showed significantly higher 
accumulation in the tumors than unmodified CREKA (Figure 3a). An exception was 
C(NMe)REKA, in which the arginine residue is N-methylated. This peptide gave only weak 
tumor fluorescence. Confocal microscopy confirmed the organ-level analyses (shown for 
CR(NMe)EKA in 22Rv1 tumors in Figure 3b and for LAPC9 tumors in Figure 3c). The active 
CREKA analogs displayed a meshwork pattern within both the viable and the necrotic lesions of 
tumor stroma that was stronger and more extensive than that seen with CREKA. As expected, 
staining of tumor sections with antibodies against fibrin(ogen) and fibronectin showed that the 
CREKA analogs accumulated in areas rich in deposition of these proteins (Figure 3b, panels on 
the right). CR(NMe)EKA and CRE(CαMe)KA appeared to be equally active in this regard 
(Figure 4).  
 
To investigate the stability of CREKA and CR(NMe)EKA in the tumor in vivo, these peptides 
were intravenously injected into mice bearing 22Rv1 tumors. The peptides gave equally strong 
fluorescence in the tumors 30 minutes after the injection (Figure 3d). However, after 3 hours the 
CREKA fluorescence had decreased by 70%, whereas CR(NMe)EKA showed no significant 
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decrease,  greater stability. Based on these observations, we selected the backbone-methylated 
peptides CR(NMe)EKA and CRE(CαMe)KA for studies with nanoparticles. 
 
Intratumoral distribution of iron oxide nanoworms coated with CREKA analogs 
 
Intravenously injected CRE(CαMe)KA-NW and CR(NMe)EKA-NW showed greatly enhanced 
accumulation in the blood vessels of the tumor rim and interior (Figure 4 and Figure 5a). These 
areas were also positive for anti-fibrin(ogen) staining. This distribution of the NW coated with the 
N/Cα-methylated peptides within tumors was markedly different from CREKA-NW, in which the 
nanoparticles appear less abundant in the interior of tumors, (compare Figures 4 and 5a with 
Figure 1a). No fluorescence from the various NW formulations was observed in normal tissues 
of the tumor-bearing mice, with the exception of the liver and the spleen, which non-selectively 
take up all nanoparticles. The liver accumulation of these NW was similar (shown for 
CR(NMe)EKA-NW in Supplementary Figure 4). Significantly more tumor accumulation of 
CR(NMe)EKA-NW than CREKA-NW was also observed in a different prostate cancer xenograft 
model, LAPC9 (Supplementary Figure 5). 
 
Magnetic resonance imaging of 22Rv1 tumor mice after intravenous injection of NW showed 
hypointense vascular signals throughout the tumor for the CR(NMe)EKA-NW, and similar, but 
weaker signals with CREKA-NW (Figure 5b). Non-targeted nanoworms gave no detectable 
signal in these tumors after most of the nanoparticles had been cleared from the blood 30. 
 
Therapeutic efficacy of tumor blood vessel blockage by peptide-coated NW 
 
Having optimized the CREKA self-amplified targeting system, by combining CREKA-NW with 
CRKDKC-NW and by incorporation of N/Cα-methylated amino acids, we tested the tumor 
treatment potential of the enhanced system. The Ni-liposome pre-treatment we used in the 
short-term experiments to block liver uptake of NW was not suitable for the long-term treatment 
experiments; it would have doubled the number of injections needed, and we also observed 
some deaths among mice that received multiple injections of Ni-liposomes. We omitted the 
liposome pre-treatment and instead coated the NW with polyethylene glycol (PEG) and coupled 
the homing peptide to the nanoparticles through the PEG chains.  
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We used the peptides bound to the NW through PEG to directly compare the in vivo stability of 
CREKA and of CR(NMe)EKA. The peptides were coupled through a reversible disulfide linkage 
to the PEG coating, and the coated NW were intravenously injected into mice bearing 22Rv1 
tumors. The NW were recovered from the blood, and the peptides were isolated and analyzed 
by mass spectrometry. CREKA and CR(NMe)EKA were equally abundant in the blood samples 
obtained after 15 minutes of circulation (Supplementary Figure 6). However, after 3 hours, 
CREKA was undetectable, indicating that all the peptide was degraded, whereas the amount of 
CR(NMe)EKA only declined by about 60%. These results show that, as intended by the 
chemical modification, CR(NMe)EKA is more stable in vivo than CREKA. CR(NMe)EKA bound 
to plasma clots with somewhat higher affinity than CREKA (Kd = 2.5 μM and 6.0 μM; 
Supplementary Figure 7), suggesting that affinity may also contribute to the superior homing 
properties of the methylated peptide. 
 
There was some loss of homing activity and clotting in tumor vessels compared to the PEG-free 
nanoparticles. We hypothesized that multiple injections might make up for this reduced activity. 
Indeed, many of the blood vessels around the necrotic area in the tumors of the mice treated for 
2 weeks with the NW combination were filled with peptide particles and deposits positive for a 
fibrin(ogen) immunostaining (Figure 6a, Supplementary Figure 8). Moreover, CEUS (Contrast-
Enhanced Ultrasound) analysis of tumors treated with the NW revealed a reduction in tumor 
blood flow; CR(NMe)EKA-PEG-NW alone gave a 30% reduction, and combining CR(NMe)EKA-
PEG-NW with CRKDKC-PEG-NW more than doubled the effect (Figure 6b, Supplementary 
Figure 9).  
 
Histological analysis of tumors from mice treated with CR(NMe)EKA-PEG-NW in combination 
with CRKDKC-PEG-NW showed extensive necrosis as evidenced by a typical loss of nuclei in 
the center of the tumors (Figure 6c). No signs of apoptosis or necrosis were observed in 
similarly sized tumors in the control groups (CRKDKC-PEG-NW and PBS). TUNEL staining 
revealed extensive apoptosis in the surviving areas of the tumors treated with CR(NMe)EKA-
PEG-NW and CRKDKC-PEG-NW combination (Figure 6d). There was highly significant 
inhibition of tumor growth in the mice treated with the combination compared with mice that 
received PBS or CRKDKC-PEG-NW alone (Figure 7a). CR(NMe)EKA-PEG-NW alone showed 
a modest but significant inhibition of tumor growth. The CR(NMe)EKA-PEG-NW and CRKDKC-
PEG-NW combination treatment also inhibited tumor growth in LAPC9 tumor mice, producing a 
Agemy et al;13 
 
significant survival increase compared to mice treated with vehicle alone (Figure 7b). These 
treatments showed no obvious systemic toxicity as evidenced by body weight measurements 
and histological analysis of organs from the treated mice. No signs of blood clotting elsewhere 
in the body (e.g. sudden death or paralysis due to stroke, pulmonary embolism, deep vein 
thrombosis) or signs of disseminated intravascular coagulation (DIC) were observed.  
 
Discussion 
  
Our results establish a tumor treatment and imaging strategy that is based on synergistic and 
self-amplifying accumulation of homing peptide-coated iron oxide NW in prostate tumor blood 
vessels. We show that extensive coverage of tumor vessels can be achieved by combining 
nanoparticles that were coated with either of two tumor-homing peptides, CREKA or CRKDKC. 
We also show that protecting the CREKA peptide against proteolysis through the incorporation 
of N/Cα-methylated residues increases the ability of the CREKA-NW to home to tumor blood 
vessels and to cause clotting in them. Combining the two approaches allowed effective MRI 
imaging of the tumors and produced extensive inhibition of tumor growth. 
 
The changes we introduced into the CREKA self-amplifying tumor vessel homing system 22 
revealed surprising cooperation of two nanoparticle species coated with different peptides. We 
had assumed that to achieve greater coverage of prostate cancer vessels, the two peptides 
should be on the same particle, but found that having them on separate particles was more 
effective. Co-accumulation with CREKA-NW was not limited to the CRKDKC peptide; NW 
coated with another tumor-homing peptide, CGKRK, also enhanced the accumulation of 
CREKA-NW in tumor vessels, albeit not as strongly as CRKDKC-NW. A likely explanation for 
this phenomenon is co-aggregation of the two species of nanoparticles, which apparently only 
happens at the high concentrations of NW achieved within tumor vessels. The clotting induced 
by the CREKA-NW may contribute to the co-accumulation by trapping loosely bound CRKDKC-
NW that would otherwise be washed away by the blood flow. Another cooperative two-particle 
nanosystem has been described recently 31.  
 
The pro-thrombotic activity of the CREKA-nanoworms is selective for tumors. This is partly 
attributable to the selective accumulation of CREKA-NW, and the NW mixture, in tumor vessels. 
Both the peptide and the iron oxide component of the nanoparticles are responsible for the 
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thrombotic activity, as other types of nanoparticles coated with CREKA and the free CREKA 
peptide lack this activity 26,32, and iron oxide NW coated with tumor-homing peptides other than 
CREKA (CRKDKC and CGKRK) also do not cause clotting. Iron oxide nanoparticles are known 
to be procoagulant, and the affinity of CREKA for clotting products apparently enhances that 
activity. The NW, like other nanoparticles, non-specifically accumulate in the liver and spleen 33. 
However, we have not observed any clotting in the normal tissues of the tumor mice in this 
study, or in an earlier study that used a similar but less effective system 22. Thus, the tumor 
environment, which is pro-coagulant 19-20, is also likely to play a role in bringing about the 
clotting in the tumor vessels. Atherosclerotic plaques tend to show subtle spontaneous clotting 
32,34
 . Thus, the presence of atherosclerosis could be a limitation in clinical application of the 
CREKA technology.   
 
The potential of peptides as drug candidates is limited by poor pharmacokinetics, which 
includes rapid elimination from the circulation through filtration into the urine and susceptibility to 
proteolysis. Elimination into the urine is not a problem with peptides coated onto a nanoparticle, 
but our results do demonstrate the importance of proteolysis. Because each nanoparticle is 
coated with multiple peptides, one might expect the nanoparticle coating to tolerate some 
proteolysis without significant loss of activity. Our results indicate that this is not the case; 
protecting the peptide against proteolytic cleavage by incorporating non-coded amino acids 
substantially improved the tumor-homing efficiency and increased the blockade of tumor 
vessels. Direct measurement of the stability of the peptides in vivo supported the conclusion 
that increased peptide stability is responsible, at least partially, for the improved characteristics 
of the methylated CREKA analogs. If extended to other peptide-coated nanoparticles, this result 
could have significant implications for the design of effective nanoparticle therapies.  
 
Here we show anti-tumor activity of our system against two orthotropic prostate cancer 
xenograft tumors, 22Rv-1 and LAPC9. It is likely that other tumor types can be similarly 
targeted, as we have shown other types of tumors to be targeted by the CREKA system 22. The 
efficiency of the combined CREKA-NW strongly correlated with the degree of tumor vessel 
blockade achieved with the various treatments. CR(NMe)EKA-PEG-NW caused 30% reduction 
in tumor blood flow, as documented by CEUS, and produced a modest reduction in tumor size. 
The CRKDKC-PEG-NW and CR(NMe)EKA-PEG-NW combination blocked 70% of tumor blood 
flow and gave a strong reduction in tumor size, as well as extended survival of the animals. 
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Significantly, these results were obtained by utilizing only the inherent properties of the NW, 
which also allowed imaging of the tumors. Adding a drug to the particles could further enhance 
the utility of this theranostic nanosystem.  
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Figure legends 
 
Figure 1. Combining CREKA NW with NW coated with another tumor-homing peptide enhances 
homing efficiency. a, Iron oxide NW coated with FAM-labeled CREKA peptide were 
intravenously injected (5 mg iron per kg body weight) into nude mice bearing orthotropic 22Rv1, 
human prostate tumors. The mice had been pre-injected with Ni-liposomes to reduce uptake by 
the reticulo-endothelial system 22. Tumors were harvested 5 hours later, and tumor sections 
were stained with antibodies and examined by confocal microscopy (the 5 hours time point was 
found to be optimal for NW homing with regard to accumulation of the NW in the tumor and 
clearance of the NW from the blood). The CREKA-coated particles are green; blood vessels and 
clotting were separately visualized with anti-CD31 (magenta) or anti-fibrin(ogen) staining (red); 
nuclei were stained with DAPI (blue). Scale bars, 200 μm. b, NW coated with FAM-labeled 
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CRKDKC or CGKRK were intravenously injected and the tissues were collected and processed 
as in (a). CRKDKC or CGKRK-coated particles are green, blood vessels visualized with anti-
CD31 (magenta; the white color indicates colocalization of magenta and green) or anti-
fibrin(ogen) staining (red; the yellow color indicates colocalization of red and green); nuclei were 
stained with DAPI (blue). Large vessels were selected for the right panels because intravascular 
clotting (which is not promoted by CRKDKC-NW or CGKRK –NW) is most apparent in larger 
vessels.  Scale bars, 200 μm in the left and middle panels; 100 μm in the right panels. c, A 
mixture of NW coated with rhodamine-labeled CREKA (red) and FAM-labeled CRKDKC (green) 
was intravenously injected (2.5 mg iron/kg of each NW preparation), and the tissues were 
collected and processed as in (a) and stained for fibrin(ogen) (magenta); nuclei were stained 
with DAPI (blue). Scale bars, 200 μm. d, Mice were injected with the indicated materials as in 
(a), (b) or (c). The sections stained with anti-fibrin(ogen) antibody were subjected to image 
analysis using Scanscope to quantify fibrin(ogen)-positive areas. The insets show examples of 
anti-fibrin(ogen) immunostaining in the tumor rim (left) and interior (right) from mice injected with 
the NW mixture. Scale bars, 50 μm. Statistical analyses were performed with ANOVA. Error 
bars, mean± SEM (n=5-6); double asterisk, p<0.01. 
 
Figure 2. Contrast Enhanced Ultrasound (CEUS) imaging of blood circulation in tumors of mice 
treated with peptide-coated NW. a, Mice pre-injected with Ni-liposomes were subsequently 
injected with a mixture of CREKA-NW and CRKDKC-NW and, after the indicated periods of 
time, injected with an ultrasound contrast agent. Contrast-enhanced and conventional 
ultrasound (US) images obtained at the different time points are shown. The images are 
representative of 3 tumors imaged. b, Enhancement analysis curves of blood flow in different 
tumor regions and the surrounding tissue from experiments described in (a). The orientation of 
the tumors is slightly different between the time points because the mice were anesthetized for 
each scan and reintroduced to the US instrument. n=3 
 
Figure 3. Tumor accumulation of the CREKA peptide and its N/Cα−methylated variants. Mice 
bearing orthotropic 22Rv1 xenograft tumors were intravenously injected with 200 μg of FAM-
labeled CREKA or N/Cα-methylated CREKA peptides and allowed to circulate for 3 hours. This 
time point highlights the differences between non-modified CREKA and some of the methylated 
variants (see panel d). The mice were perfused through the heart with PBS, and the organs 
shown were collected and viewed under UV light. a, Quantification of fluorescence with Image J 
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software. Several N/Cα-methylated CREKA analogs produced stronger fluorescence than 
unmodified CREKA. Statistical analyses were performed with ANOVA. Error bars show mean ± 
SEM (n=3-4); double asterisk, p<0.01; triple asterisk p<0.001. Representative images from mice 
injected with the CREKA or CR(NMe)EKA peptides b, 22Rv-1 and c, LAPC9 xenografts. In the 
upper panels, white dotted lines show where the organs were placed in a macroscopic 
examination, and the yellow line outlines the tumor. The lower panels show confocal images of 
tumor sections from mice injected with the peptides (green) indicated above. Blood vessels 
were visualized with anti-CD31 (red); nuclei were stained with DAPI (blue). Scale bars, 200 μm. 
The right panels (b) show representative confocal image fields to illustrate the localization of the 
CR(NMe)EKA peptide (green) in relation to anti-fibrin(ogen) (red) and anti-fibronectin (magenta) 
staining used as markers of tumor stroma; nuclei were stained with DAPI (blue). Scale bar, 50 
μm. The right panels (c) show quantification of fluorescence with Image J software. Statistical 
analysis was performed with Student’s t-test. Error bars show mean ± SEM (n=3); double 
asterisk, p<0.01.  d, Quantification of fluorescence with Image J software 15 minutes or 3 hours 
after peptide injection to 22Rv1 tumor mice. CR(NMe)EKA produced stronger fluorescence over 
time compared to unmodified CREKA. Statistical analysis was performed with Student’s t-test. 
Error bars show mean ± SEM (n=3-4); triple asterisk p<0.001. (NMe) and (CMe) indicate an N- 
or Cα-methylated residue, respectively.  
 
Figure 4. CRE(CMe)KA-NW homing to 22Rv1 tumors. Mice bearing orthotropic 22Rv1 
xenograft tumors were intravenously injected with 200 μg of FAM-labeled CRE(CMe)KA or 5 mg 
iron/kg of NW coated with FAM-CRE(CMe)KA. The peptide was allowed to circulate for 3 hours 
and NW were allowed to circulate for 5 hours. The mice were then perfused through the heart 
with PBS, and the tumors were collected. Tumor sections were stained with CD31 or anti-
fibrin(ogen) (red) and examined by confocal microscopy. NW are green; nuclei were stained 
with DAPI (blue). Scale bars, 200 μm. n=3.  
 
Figure 5. Improved tumor homing of NW coated with an N-methylated CREKA peptide analog. 
NW coated with FAM-labeled CREKA peptide or its N-methylated variant, CR(NMe)EKA, were 
intravenously injected into mice bearing 22Rv1 tumors (total dose 5 mg iron/kg). a, Tumors 
were harvested 5 hours later, and tumor sections were stained with antibodies and examined by 
confocal microscopy. CR(NMe)EKA-NW are green; blood vessels and clotting were separately 
visualized with anti-CD31 or anti-fibrin(ogen) staining (red). Nuclei were stained with DAPI 
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(blue). Scale bars, 100 μm (50 μm in the inset). b, T2-weighted MR images (Fast Spin Echo, 
TR=6.4s, TE=69ms). CREKA-NW or CR(NMe)EKA-NW were intravenously injected into tumor-
bearing mice. The particles were allowed to circulate for 7-8 hours (the time determined in 
preliminary experiments to be optimal for differential homing). Gray scale images of axial planes 
through the tumors are shown. Gadolinium (Gd) and Feridex (Fe) were used as reference 
standards. n=3-4. 
 
Figure 6. NW distribution and effects on intravascular clotting, tumor apoptosis and tumor 
therapy. Mice bearing 2 week-old orthotopic xenografts of 22Rv1 human prostate cancer were 
intravenously injected with NW coated with peptides through a 5-kDa polyethylene glycol 
spacer. The NW were administered every other day for 14 days (5 mg iron/kg/day, total 
cumulative dose 35 mg/kg). a, Tumor sections were stained with anti-CD31 (red); 
CR(NMe)EKA-NW/CRKDKC-NW combination (green); nuclei were stained with DAPI (blue). 
Scale bars, 200 μm. Note: The necrotic area at the center of the tumor is autofluorescent. b, 
CEUS imaging and analysis showing reduction in tumor blood flow at the end of the treatment. 
The image are representative of n=3. c, H&E staining showing a large necrotic area (arrow) in 
the middle of a typical tumor treated with the CR(NMe)EKA-NW/CRKDKC-NW combination and 
occluded vessels in the viable rim of these tumors (broken arrows). A tumor of a similar size 
from a mouse treated with CRKDKC-NW alone is shown for comparison. d. Apoptosis analysis 
by TUNEL staining (red); NW combination (green); nuclei were stained with DAPI. Scale bars, 
200 μm.  
  
Figure 7. Tumor treatment with targeted nanoworms. Mice bearing orthotopic xenografts of 
22Rv1 or LAPC9 human prostate cancer (2 weeks or 10 days after the inoculation, respectively) 
were intravenously injected with NW coated with peptides through a 5-kDa polyethylene glycol 
spacer. The particles were administered every other day for 14 days (5 mg iron/kg/day, total 
cumulative dose 35 mg/kg). a, Tumor volume one day after the last injection in the 22Rv1 model 
is shown. Statistical analyses were performed with ANOVA . Error bars show mean ± SEM 
(n=10-12); double asterisk, p<0.01; triple asterisk p<0.001. Similar results were obtained in two 
independent experiments. b, Mice bearing LAPC9 tumors were treated as described in (a) and 
survival was monitored over time (n=8 per group). The arrow indicates the day the NW 
treatment was stopped.  
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